10/18/2024

Janusmed sex and gender

Janusmed sex and gender – darunavir

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
A A
A A

Darunavir

Darunavir

Class : A

Show all info

Print

Contact us

  1. PREZISTA (darunavir). Summary of Product Characteristics. European Medicines Agency (EMA); 2009.

  2. Schöller-Gyüre M, Kakuda TN, Sekar V, Woodfall B, De Smedt G, Lefebvre E et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 2007;12:789-96.

  3. Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L et al. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. J Med Virol. 2013;85:8-15.

  4. Patterson K, Jennings S, Falcon R, Mrus J, Kashuba A. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother. 2011;55:1120-2.

  5. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11-8.

  6. Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.

  7. Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-57.

  8. Fourie J, Flamm J, Rodriguez-French A, Kilby D, Domingo P, Lazzarin A et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96. HIV Clin Trials. 2011;12:313-22.

  9. Currier JS, Martorell C, Osiyemi O, Yin MT, Ryan R, De La Rosa G et al. Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS. 2011;25:333-40.

  10. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.

  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.]

  1. PREZISTA (darunavir). Summary of Product Characteristics. European Medicines Agency (EMA); 2009.
  2. Schöller-Gyüre M, Kakuda TN, Sekar V, Woodfall B, De Smedt G, Lefebvre E et al. Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 2007;12:789-96.
  3. Ghosn J, Slama L, Chermak A, Houssaini A, Lambert-Niclot S, Schneider L et al. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1. J Med Virol. 2013;85:8-15.
  4. Patterson K, Jennings S, Falcon R, Mrus J, Kashuba A. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women. Antimicrob Agents Chemother. 2011;55:1120-2.
  5. Haubrich R, Berger D, Chiliade P, Colson A, Conant M, Gallant J et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS. 2007;21:F11-8.
  6. Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395-402.
  7. Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-57.
  8. Fourie J, Flamm J, Rodriguez-French A, Kilby D, Domingo P, Lazzarin A et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ ritonavir in HIV-1-infected, treatment-naïve ARTEMIS patients at week 96. HIV Clin Trials. 2011;12:313-22.
  9. Currier JS, Martorell C, Osiyemi O, Yin MT, Ryan R, De La Rosa G et al. Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks. AIDS Patient Care STDS. 2011;25:333-40.
  10. Else LJ, Taylor S, Back DJ, Khoo SH. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther. 2011;16(8):1149-67.
  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-05-20.]